



Kentucky Public Health

Prevent. Promote. Protect.

Immunization Branch

COVID-19 VACCINATION GUIDANCE FOR THOSE INDIVIDUALS VACCINATED OUTSIDE THE US

Received all doses of **FDA approved/authorized or WHO emergency listed** COVID-19 vaccine?

FDA Approved/Authorized or WHO Qualified COVID-19 Vaccines

Manufacturer	Dose	FDA Approved or Authorized	WHO Qualified
Pfizer-BioNTech Comirnaty	2 doses; 21 days apart	yes	yes
Moderna	2 doses; 28 days apart	yes	yes
J&J Janssen	1 dose	yes	yes
AstraZeneca Vaxzervria	2 doses; 4-12 weeks apart	no	yes
Serum Institute of India COVISHIELD	2 doses; 4-12 weeks apart	no	yes
SinoPharm Covilo/BBIBP-CorV	2 doses; 21-28 days apart	no	yes
Sinovac CoronaVac	2 doses; 14-28 days apart	no	yes

[BC Centre for Disease Control ; World Health Organization \(WHO\) Emergency Use Authorization \(EUA\) Qualified COVID-19 Vaccines](#) used to ascertain WHO qualified vaccine dosing schedule

Yes
No further doses needed

- Under the [EUI](#), moderately or severely immunocompromised people aged ≥ 12 years should receive an additional primary dose of Pfizer-BioNTech at least 28 days after receiving the second vaccine dose of their primary series as detailed
- Under the [EUI](#), people aged ≥ 18 years (including moderately or severely immunocompromised people who received an additional primary dose) are eligible to receive a single booster dose of Pfizer-BioNTech COVID-19 vaccine at least 6 months after completing their primary series,

No
Only received 1 dose of **FDA approved/authorized** 2 dose series

Should receive 2nd dose. Do not restart series

May receive booster in 6 months or receive 3rd additional dose in 28 days if immunocompromised

No
Vaccine not approved or authorized in US

Partial **WHO-authorized** series completed

All or some of a **non-WHO authorized** series completed

May receive the complete **FDA approved/authorized** vaccine series 28 days after receipt of the previously received COVID vaccine

No additional doses or boosters approved at this time

[Centers for Disease Control and Prevention. \(2021.OCT. 25\). Interim Clinical Consideration for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.](#)